|
|
|
Volumn 17, Issue 4, 2007, Pages 463-473
|
|
New therapeutic strategy of rheumatoid arthritis to reach the goal of suppression of joint destruction
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIRHEUMATIC AGENT;
IMMUNOGLOBULIN G;
INFLIXIMAB;
METHOTREXATE;
MONOCLONAL ANTIBODY;
TNFR FC FUSION PROTEIN;
TNFR-FC FUSION PROTEIN;
TUMOR NECROSIS FACTOR ALPHA;
TUMOR NECROSIS FACTOR RECEPTOR;
UNCLASSIFIED DRUG;
CLINICAL TRIAL;
DRUG COMBINATION;
HUMAN;
IMMUNOLOGY;
JOINT;
PATHOLOGY;
REVIEW;
RHEUMATOID ARTHRITIS;
ANTIBODIES, MONOCLONAL;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
CLINICAL TRIALS;
DRUG THERAPY, COMBINATION;
HUMANS;
IMMUNOGLOBULIN G;
JOINTS;
METHOTREXATE;
RECEPTORS, TUMOR NECROSIS FACTOR;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 34250178808
PISSN: 09175857
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (3)
|
|
References (30)
|
